Eliyahou Et Al Harari, 10% Owner at CapsoVision, Inc (CV), bought 13,850 shares at $7.35 ($102K) on 2026-06-26, disclosed to the SEC on 2026-07-07.
Eliyahou Et Al Harari purchased 13,850 shares of CapsoVision at $7.35 on June 26, 2026, representing the largest insider purchase in the company's history. This significant buy signals confidence in the company's AI-driven capsule endoscopy platform despite recent stock volatility.
The stock has crashed 24.5% over the past five days and is currently trading 26.32% below its 52-week high of $7.695, sitting near the 52-week low of $5.64.
The FDA 510(k) submission for the AI-Assisted Module in CapsoCam Plus on January 2, 2026, remains a key regulatory milestone; the Q1 2026 earnings call on May 14, 2026, provided updates on commercial growth and regulatory milestones; and the insider purchase of 13,850 shares on June 26, 2026, acts as a near-term catalyst for investor attention.
The stock faces risk from a significant recent price decline of 24.5% over the past five days and a negative net buyer flow of -1.0 over the last 90 days. Additionally, the company operates in a competitive medical device sector with a short interest of 3.92% of the float.
Negative factors outweigh the positive ones.
| Filing → |
| CV | BUY | 2026-07-10 | $495K | — | Filing → |
| SNDK | SELL | 2010-12-02 | $5.8M | — | Filing → |
| SNDK | SELL | 2010-11-03 | $937K | — | Filing → |